Examining how history has shaped women’s reproductive health access and what role Afaxys plays in prioritizing access, affordability and innovation will be discussed at the next SCbio Women in Life Sciences Breakfast. Hear from Ronda Dean, corporate board director and executive leader at Afaxys, a first-of-its-kind, socially conscious healthcare company whose name is derived from a combination of affordability and access. With community and public health providers as partners, the company ensures that dependable and affordable contraceptive care is available to everyone.
Attendees will learn from Dean’s experience and how she leads with purpose. The regional breakfast will be held on Tuesday, August 26, at 8 a.m. in Charleston and is sponsored by Womble Bond Dickinson, Poly-Med Inc. and Town of Mount Pleasant Economic Development.
Dean is an accomplished chief executive with a strong track record of robust and sustainable growth for start-up and established corporate and non-profit entities. As an industry thought leader in women’s reproductive health, she spent her career making a positive impact in people’s lives and building resilient, high-performance organizations. Dean has led multiple corporate and not-for-profit start-ups and build-outs, including a business unit of a Fortune 100 company, a private foundation and an industry-pioneering spin-off serving a national customer base.
Dean founded Afaxys in 2008 and has led the successful execution of the company’s start-up operations and capitalization strategy. In year one, the company launched its first product, a group purchasing organization for public health providers. It expanded operations into the pharmaceutical sector in 2013 and is now the largest supplier of contraceptives to clinics in the U.S. public health system. Afaxys owns and operates several wholly owned subsidiaries, including Afaxys Pharma LLC, Afaxys Drug Development LLC and Afaxys Group Services LLC.
Prior to the start of Afaxys, Dean spent 16 years with Parke-Davis Pharmaceuticals, a division of Warner-Lambert, where she progressed quickly into executive management. Before the company’s merger with Pfizer, she served as vice president and general manager of Parke-Davis Women’s Healthcare, leading a $300M business unit through a period of accelerated growth. This expansion firmly established Parke-Davis as a leader in the women’s healthcare category, building it from a small, one-category business to a multi-category, key revenue and profit generator. During this time, Dean served on the company’s Executive Management Team, providing strategic and operational guidance to the U.S. pharmaceutical business.
Having served on several for-profit and non-profit boards, Dean brings expertise and deep experience to the boardroom. Her current and previous board experience includes the Coastal Community Foundation of South Carolina, Johns Hopkins Medical Institution, Storm Eye Institute at the Medical University of South Carolina, the New Morning Foundation, Wings for Kids and Afaxys Inc.
Dean holds a Bachelor of Science in Allied Medicine from Ohio State University and a Master of Business Administration from Fuqua School of Business at Duke University.